The American Society of Transplantation Online Transplant Infectious Diseases Library
Full Library 1,563 resources
-
Abstract Combination antifungal therapy for invasive mucormycosis remains controversial and is inconsistently defined in prior studies. In a cohort of immunocompromised patients with invasive mucormycosis, we found no difference in 6-week mortality with upfront nor salvage combination therapy compared to monotherapy.
-
Histoplasmosis is an endemic and invasive mycosis caused by Histoplasma capsulatum. We conducted a retrospective study comparing non-HIV immunosuppressed patients with a historical cohort of HIV and histoplasmosis. We included 199 patients with proven or probable histoplasmosis, of which 25.1% were non-HIV. Diabetes mellitus, chronic kidney disease, hematologic neoplasms, rheumatologic diseases and transplants were more frequent among non-HIV patients (p<0.01). Death after diagnosis...
-
Febrile neutropenia (FN) is common among hematologic malignancy patients, including recipients of hematopoietic cell transplantation (HCT) and cellular therapies such as chimeric antigen receptor (CAR)-T-cell therapy. Prompt empiric antibiotic use has been the mainstay for decades but a “one-size-fits-all” approach is no longer broadly accepted, as treatment-related infectious risk are more understood. Growing antimicrobial resistance is an increasing clinical challenge. Evolving strategies...
-
Abstract Background Infectious diseases (ID) are highly relevant after solid organ transplantation in terms of morbidity and mortality, being among the most common causes of death. Patients undergoing kidney re-transplantation (re-K-Tx) have been already receiving immunosuppressive therapy over a prolonged period potentially facilitating subsequent infections. Comparing ID events after re-K-Tx and first kidney transplantation (f-K-Tx) can delineate...
-
Background: Neuraminidase inhibitors, including oseltamivir, are the treatment standard for influenza. Baloxavir, a novel antiviral, demonstrated comparable outcomes to oseltamivir in outpatients with influenza. Baloxavir was equally effective as oseltamivir in a retrospective study of hospitalized patients with influenza at our institution. However, the efficacy of baloxavir in immunocompromised patients is unclear. Methods: We conducted a retrospective cohort study of immunocompromised...
-
Histoplasma capsulatum, the etiological agent for histoplasmosis, is a dimorphic fungus that grows as a mold in the environment and as a yeast in human tissues. It has a broad global distribution with shifting epidemiology during recent decades. While in immunocompetent individuals infection is usually self-resolving, solid organ transplant recipients are at increased risk of symptomatic disease with dissemination to extrapulmonary tissue. Diagnosis of histoplasmosis relies on direct...
-
The diagnosis of nontuberculous mycobacterial infections is challenging in pediatric solid organ transplant and hematopoietic cell transplant recipients due to the absence of specific clinical manifestations, limitations of sampling, prolonged times for culture and identification, and difficulty discerning colonization from clinical disease. Treatment is dependent on the nontuberculous mycobacterial species, disease type, and pattern of drug resistance. Treatment of nontuberculous...
-
Fluoroquinolones (FQs) are effective for oral step-down therapy for gram-negative bloodstream infections but are associated with unfavorable toxic effects. Robust data are lacking for trimethoprim-sulfamethoxazole (TMP-SMX) and high-bioavailability β-lactams (HBBLs).In this multicenter observational cohort study, we simulated a 3-arm registry trial using causal inference methods to compare the effectiveness of FQs, TMP-SMX, or HBBLs for gram-negative bloodstream infections oral step-down...
-
Respiratory viral infections (RVIs) are among the leading cause of morbidity and mortality in pediatric hematopoietic stem cell transplant (HCT) and solid organ transplant (SOT) recipients. Transplant recipients remain at high risk for super imposed bacterial and fungal pneumonia, chronic graft dysfunction, and graft failure as a result of RVIs. Recent multicenter retrospective studies and prospective studies utilizing contemporary molecular diagnostic techniques have better delineated the...
-
Viral infections are a major source of morbidity and mortality in the context of immune deficiency and immunosuppression following allogeneic hematopoietic cell (allo-HCT) and solid organ transplantation (SOT). The pharmacological treatment of viral infections is challenging and often complicated by limited efficacy, the development of resistance, and intolerable side effects. A promising strategy to rapidly restore antiviral immunity is the adoptive transfer of virus-specific T cells (VST)....
-
Pediatric Infectious Disease (ID) clinicians play a critical role in helping prevent and mitigate infectious risks in children peri- and post-transplantation. Prevention starts during the pre-transplant evaluation and persists throughout the solid organ transplant and hematopoietic cell transplant continuum. The pre-transplant evaluation is an opportunity to screen for latent infections, plan preventative strategies, optimize immunizations, and discuss risk mitigation practices. An ideal...
-
Invasive fungal disease (IFD) remains a significant cause of morbidity and mortality in children undergoing transplantation. There is a growing armamentarium of novel antifungal agents recently approved for use or in late stages of clinical development. The overarching goal of this review is to discuss the mechanisms of action, spectrum of activity, stage of development, and pediatric-specific data for the following agents: encochleated amphotericin B deoxycholate, fosmanogepix,...
-
To theEditor—Invasive fusariosis (IF) is a severe opportunistic mold infection that often results in poor outcomes, especially for patients with hematological malignancies [1–4]. Skin involvement is the second most common manifestation of IF after pulmonary involvement [1–3]. While in vitro studies showed synergistic effects of the squalene epoxidase inhibitor terbinafine (TRB) when combined with triazoles [5] or liposomal amphotericin B (L-Amb) [6] against various fungal pathogens,...
-
Abstract Among 1107 cryptococcosis cases from the French surveillance network (2005–2020), the proportion of HIV-seronegative individuals has recently surpassed that of HIV-seropositive individuals. We observed marked differences in patient characteristics, disease presentations, cryptococcal antigen results, infecting species, and mortality according to HIV serostatus.
-
Despite current prophylaxis regimens, cytomegalovirus (CMV) is common in hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) and remains a significant cause of morbidity and mortality. Newer antiviral medications are reshaping the landscape for prevention and treatment of CMV DNAemia, infection, and disease. Letermovir is approved for CMV prevention in adult HCT patients and is attractive due to the absence of marrow suppression seen with...
-
Epstein-Barr Virus (EBV) diseases, including EBV-associated post-transplant lymphoproliferative disorder (PTLD) remain important causes of morbidity and mortality in children undergoing solid organ transplantation (SOT) and hematopoietic cell transplantation (HCT). Despite progress in the prevention of EBV disease including PTLD (EBV/PTLD) in HCT, key questions in the prevention, and management of these infectious complications remain unanswered. The goal of this manuscript is to highlight...
Filter by our tag
GUIDELINES
- AASLD Guidelines (5)
- AST Guidelines 2019 (44)
- ASTCT Guidelines 2019-2023 (9)
- DGHO Guidelines (3)
- ECIL Guidelines (20)
- ESCMID Guidelines (25)
- IDSA Guidelines (53)
- ISHLT Guidelines (12)
- NIH Guidelines (1)
- WHO Guidelines (1)
- WikiGuidelines (3)
TEXTBOOKS
CORE CURRICULUM
- BASICS OF TRANSPLANT (35)
- ORGANISMS (44)
- SYNDROMES (13)
ORGANISMS
-
BACTERIA
(159)
- C. difficile (25)
- Legionella (1)
- MDR GNR (38)
- MRSA (7)
- Mycoplasma and Ureaplasma (11)
- Nocardia (11)
- Non-tuberculous Mycobacteria (27)
- Syphilis (6)
- Tuberculosis (33)
- VRE (8)
-
FUNGI
(227)
- Aspergillus (59)
- Candida (48)
- Cryptococcus (29)
- Endemic mycoses (43)
- Mucormycosis (33)
- Pneumocystis (41)
- Rarer Fungi (22)
-
PARASITES AND PROTOZOA
(44)
- Chagas (10)
- Protozoa (12)
- Strongyloides (14)
- Toxoplasmosis (12)
-
VIRUSES
(418)
- Adenovirus (17)
- Arboviruses (7)
-
CMV
(121)
- Cell-Mediated Immunity Assays (11)
- Clinical (56)
- Cytotoxic T-Lymphocytes (1)
- Epidemiology and Risk Factors (15)
- Letermovir (25)
- Maribavir (16)
- Preemptive Therapy (7)
-
COVID-19
(50)
- Diagnosis (4)
- Fungal superinfection (2)
- GUIDELINES (11)
- Infection Prevention (4)
- Positive Donors (6)
- Positive Recipients (5)
- Treatments (20)
- Vaccination (9)
- Hepatitis A (2)
- Hepatitis B (29)
- Hepatitis C (31)
- Hepatitis D (5)
- Hepatitis E (5)
- HHV-6 (23)
- HHV-8 (4)
- HIV (31)
- HPV (5)
- HSV (4)
- Influenza (17)
- Measles (21)
- Mpox (6)
- Norovirus (8)
- Parvovirus B19 (3)
- Polyomaviruses (32)
- Respiratory Viruses (31)
- RSV (18)
- VZV (17)
- WNV (2)
DIAGNOSTICS
- Advanced Diagnostics (23)
- Fungal diagnostics (40)
- Nuclear Medicine (7)
- Parasites (3)
- Procalcitonin (1)
- Viral diagnostics (1)
DRUGS AND THERAPIES
- Antibiotics (12)
- Antifungals (69)
- Antivirals (10)
- Cytotoxic T-lymphocyte therapy (7)
- Fecal Microbiota Transplantation (12)
- Phage therapy (4)
- Stewardship (57)
PREVENTION
- Infection Control (8)
- Safe Living (22)
- Travel (10)
- Vaccination (39)
SYNDROMES AND CONDITIONS
- Cirrhotics (11)
- CNS (3)
- Cytopenias (2)
- Diarrhea (13)
- Endovascular infections (12)
- Pneumonia (11)
- Surgical Infections (8)
- UTI (31)
SOLID ORGANS AND MCSS
- Donor (43)
- Heart (15)
- Immunosuppression (14)
- Intestinal (2)
- Kidney (32)
- Liver (53)
- Lung (69)
- LVAD (31)
- Pancreas (5)
- PEDIATRIC (43)
- Recipient (5)
- Total Artificial Heart (1)
- Vascular Composite Allograft (2)
- Xenotransplantation (3)
HEME-ONC AND CELLULAR THERAPIES
- Biologics (45)
- BMT Basics (5)
- BMT Guidelines (14)
- BMT Noninfectious (12)
- BMT-specific ID (71)
- CAR-T (21)
- CAR-T Noninfectious (3)
- GVHD (4)
- Heme malignancies (4)
- Heme-onc prophylaxis (25)
- Neutropenia (43)
- PEDIATRIC (33)
- PTLD (25)
- TK inhibitors (12)
TRANSPLANT ID TRAINING
- AST (4)
- Career Development (1)
- Fungal (5)
- Training program (7)
PATIENT EDUCATION
- COVID-19 (13)
- Food (10)
- Hygiene (4)
- Mpox (5)
- Pets (4)
- Safer living (16)
- Selected Infections (10)
- TB (10)
- Travel (3)
- Water safety (5)
JOURNAL CLUB
- 2024 (2)